A run of bad luck for developers of potential treatments for diffuse large B-cell lymphoma – Roche, Celgene and Novartis – has withered the late-stage pipeline for an indication that has long been in need of new therapies. Scrip and Datamonitor Healthcare take a look at what's next for the disease.
The series of clinical trial failures in diffuse large B-cell lymphoma (DLBCL) means that a significant market opportunity will remain unaddressed for the near future.
In the past three months, no fewer than three Phase III trial failures have been announced for products being investigated...
Create an account to read this article
Already a subscriber?
Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.
The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.
François Roger believes fixing inefficiencies is more important than playing with pricing.
The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.
The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.
Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.
Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.
